In the United States alone, about 50,000 people are diagnosed with Parkinson’s disease every year. Of the estimated one million Americans who have the degenerative disorder, roughly half will experience hallucinations or delusions associated with Parkinson’s disease.
The effects of Parkinson’s disease psychosis can be disturbing and debilitating for both patients and family members. That’s why countless people were so excited and hopeful when antipsychotic drug Nuplazid was approved by the U.S. Food and Drug Administration in 2016 to treat hallucinations and delusions in patients with Parkinson’s disease.
Unfortunately, shortly after the drug’s approval, the FDA started receiving thousands of reports of adverse effects, including more than 700 deaths associated with Nuplazid.
Learn more about how the drug was approved and why family members of those taking Nuplazid are considering lawsuits against drugmaker Acadia Pharmaceuticals.